Abstract
Transcutaneous aortic valve replacement (TAVR) is known to improve patient survival in inoperable aortic stenosis. However, data is limited about performing TAVR in patients with underlying malignancy. Hence, we hypothesized to study clinical outcomes of performing TAVR in these patients. We
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
